Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation)

scientific article published on 01 May 2018

Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1161/CIRCOUTCOMES.117.003971
P698PubMed publication ID29752388

P50authorSteven P SedlisQ42328564
Daniel S BermanQ89697826
P2093author name stringPhilip Jones
William S Weintraub
Zugui Zhang
William E Boden
G B John Mancini
John A Spertus
Koon Teo
David J Maron
Pamela Hartigan
William Kostuk
P433issue5
P921main subjectcoronary artery diseaseQ844935
P304page(s)e003971
P577publication date2018-05-01
P1433published inCirculation: Cardiovascular Quality and OutcomesQ15816436
P1476titlePredicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation)
P478volume11

Reverse relations

Q64111041Chitosan Oligosaccharides Show Protective Effects in Coronary Heart Disease by Improving Antioxidant Capacity via the Increase in Intestinal Probioticscites workP2860

Search more.